JB Chemicals and Pharma has emerged in a new avatar as JB, retaining its core value of being ‘Good people for good health.’ The company announced its new identity at a media conference organised last week in Mumbai.
As per a company statement, JB has re-visioned the cause of spreading good health in India. It aims to support healthcare providers and enrich patients’ lives in innovative new ways while remaining committed to its core values of integrity, trust and reliability built over 45 years.
Announcing the change of identity to JB – Good People for Good Health, Nikhil Chopra, CEO and Whole-time Director, JB, said in the statement, “In 45 years, we, at JB, have built a strong foundation of integrity, trust and reliability. Now, we are taking the next leap forward towards becoming more agile, lean and simple. Our offerings and capabilities are becoming more diverse to cater to the evolving needs of our customers, our manufacturing processes are becoming more robust and lean, and our vision of looking at the healthcare industry is becoming more progressive, globally. We are adapting ourselves to become more responsive to the needs of the healthcare world.”
In FY21-22, the company recorded revenue of Rs 2,424 crores as compared to Rs 2,043 crores in FY20-21, registering a growth of 19 per cent. The sales growth for the last quarter was 18 per cent, and domestic formulations continued to record a growth of 30 per cent. According to MAT Mar’ 2022, JB grew at 29 per cent versus market growth of 18 per cent; and, as per the last quarter of FY22, it grew at 21 per cent versus market growth of 10 per cent. Moreover, six new products were launched in the last quarter of FY22, with over 15 key new launches, excluding product line extensions. The company’s international business has also bounced back in the fourth quarter of FY21-22, witnessing double-digit growth across segments with a growth rate of nine per cent YoY, the statement concluded.